Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 09:28am CEST

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

The dispute between the Jordan-based firm, its partner Vectura (>> Vectura Group PLC) and the U.S FDA delays any eventual approval of the generic version of the drug.

Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

Hikma, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million citing higher pricing pressures in the industry, having slashed it to $670 million from an initial $800 million last November.

The company, that has been hit by higher price erosion levels than the rest of the industry, has been re-negotiating its contracts with suppliers and third-party vendors to cut costs to try to boost profitability.

"We expect these market conditions to persist in 2018 and are actively pursuing new commercial opportunities and focussing on the execution of our pipeline to help offset continuing price erosion across the industry," it said in a statement.

The company, which cut its full-year guidance in May to the range of $2 billion-$2.1 billion from $2.2 billion, said in August that it expected 2017 revenue to be at the lower end of the range at $2 billion.

Hikma reiterated its 2017 revenue expectations on Thursday.

Earlier this month, Israeli-based Teva Pharmaceutical (>> Teva Pharmaceutical Industries Limited), the world's biggest generics drugmaker, said it would miss 2017 profit forecasts citing falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug.

Hikma's lower guidance in May followed a decision by U.S. regulators not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application.

Hikma said it expected the dispute process with the FDA to be completed in the first quarter of 2018.

(Reporting by Justin George Varghese in Bengaluru and Ben Hirschler in London; editing by Jason Neely and Keith Weir)

Stocks mentioned in the article
ChangeLast1st jan.
HIKMA PHARMACEUTICALS -2.31% 1229 Delayed Quote.10.93%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2.86% 6465 Delayed Quote.-3.41%
VECTURA GROUP PLC -5.63% 82.1 Delayed Quote.-26.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
07:38pGlaxoSmithKline's Trelegy Ellipta Gets Expanded Indication From FDA
DJ
06:56pGLAXOSMITHKLINE : Once-Daily Trelegy Ellipta Gains Expanded Indication in the US..
BU
06:47pGLAXOSMITHKLINE : Trelegy Ellipta expanded US COPD indication
PU
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20P&G's vitamin boost could signal more to come
RE
04/19GLAXOSMITHKLINE : New Gingivitis Study Results from GlaxoSmithKline plc Describe..
AQ
04/19GLAXOSMITHKLINE : An Application for the Trademark "DOVATOR" Has Been Filed by G..
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "ABREVA" Filed by GlaxoSmithKline
AQ
04/19GLAXOSMITHKLINE : Trademark Application for "DOVIPSA" Filed
AQ
04/19GLAXOSMITHKLINE : Reports Summarize Vaccines Study Results from GlaxoSmithKline ..
AQ
More news
News from SeekingAlpha
03:23pFDA OKs expanded use for Glaxo's Trelegy Ellipta 
02:28pBY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
01:42aJF'S CORE BIOTECH BUYS #12 : Updates And Introducing Our 18th Selection 
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/19Novartis Q1 results weigh on pharma stocks 
Financials ( GBP)
Sales 2018 29 847 M
EBIT 2018 8 147 M
Net income 2018 3 877 M
Debt 2018 17 415 M
Yield 2018 5,55%
P/E ratio 2018 17,81
P/E ratio 2019 15,39
EV / Sales 2018 2,96x
EV / Sales 2019 2,85x
Capitalization 70 913 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 15,5  GBP
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE9.26%98 888
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571